Correlation between Hasford Score with Early Molecular Response in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib

I. Dewa Made Widi Hersana*¹, Ugroseno Yudho Bintoro¹, Ami Ashariati¹ and Made Putra Sedana¹

¹Hematology and Medical Oncology Division, Department of Internal Medicine, Universitas Airlangga-Dr Soetomo Teaching Hospital, Surabaya, Indonesia.

Corresponding Author E-mail: widihersana@yahoo.com

Abstract: The aim of the study is to to determine correlation Hasford score and early molecular response in chronic phase BCR-ABL-Positive CML patients treated with imatinib. This is an longitudinal observational study in newly diagnosed patients of CML chronic phase BCR-ABL-Positive treated imatinib from Januari 2017 to September 2017. Patients were stratified according to Hasford score at diagnosis. Q-PCR(Quantitative RT-PCR) were used to monitor BCR-ABL transcription levels after 3 months of imatinib treatment.  Correlation between Hasford score with early molecular response were analyzed using Koefisien Kontingensi’s correlation test. Results: Thirty five patients were enrolled in this study consist of 13 male and 22 female. After 3 months of imatinib treatment, EMR were 5 patients (83.3%), 11 patients (61.1%) and 2 patients (18.2%) in low, intermediate, and high risk group patients, respectively. Koefisien kontigensi test showed that there was significant correlation between Hasford score and EMR (p=0.018; r=0.431). The Hasford score correlated to early molecular response in chronic phase BCR-ABL-positive CML patients received imatinib.

Keywords: Chronic Phase BCR-ABL-Positive CML; Early Molecular Response; Hasford Score; Imatinib

[ HTML Full Text]

Back to TOC